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Superficial mycoses caused by dermatophytic fungi such as Trichophyton rubrum
represent the most common type of worldwide human infection affecting various
keratinized tissues in our body such as the skin, hair, and nails, etc. The dermatophytic
infection is a significant public health threat due to its persistent nature and high
recurrence rates, and thus alternative treatments to cure this fungal infection are urgently
required. The present study mainly focused on the synergistic activity of violacein with
four azole drugs (ketoconazole, fluconazole, clotrimazole, and itraconazole) against T.
rubrum. The synergistic antifungal activities of violacein and azoles were measured by
checkerboard microdilution and time-kill assays. In our study, combinations of violacein
and azoles predominantly recorded synergistic effect (FIC index < 0.5). Significant
synergistic value was recorded by the combination of violacein and clotrimazole. Time-kill
assay by the combination of MIC concentration of violacein and azoles recorded
that the growth of the T. rubrum was significantly arrested after 4–12 h of treatment.
The combination of violacein and azoles leads to the enhanced inhibition of mycelial
growth and conidial germination. Moreover combination enhanced the rate of release
of intracellular materials. Morphological changes by SEM analysis were also prominent
with the combination. A normal human cell line [Foreskin (FS) normal fibroblast] was
used to check the cytotoxicity of violacein. Interestingly violacein recorded no cytotoxicity
up to 100µg/ml. The in vitro synergistic effect of violacein and azoles against clinically
relevant fungi, T. rubrum, is reported here for the first time. Finally, our findings support
the potential use of the violacein as an antifungal agent especially against dermatophytic
fungi T. rubrum.
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Introduction
Antimicrobial resistances (AMR) in superficial fungal infections
are a major worldwide public health problem that affects
more than 30% of the human population globally (Asticcioli
et al., 2008). Among these fungal diseases, dermatophytosis, or
tinea, is one of the most frequently encountered human fungal
infections. This infection is caused by various dermatophytic
fungal species belonging to the Trichophyton, Microsporum, or
Epidermophyton genera (Soares et al., 2014). Dermatophytosis is
a type of superficial fungal infection produced by dermatophytes,
a group of keratinophilic fungi that usually infect the keratinized
tissues of our body such as nails, skin, and hair, etc. (Baltazar
et al., 2013). This infection mainly occurs in immunocompetent
and immunocompromised peoples. Trichophyton rubrum is the
most important causative agent of fungal infections affecting
various keratinized tissues (Baltazar et al., 2013). T. rubrum
mainly affect nails (onychomycosis) a dermatophytosis of high
incidence, and it’s very rapid evolution may be observed as one
of the major indicator of immunodeficiency conditions such as
HIV infection and this infection is of significant risk to cancer
patients undergoing chemotherapy (Almeida, 2008; Baltazar
et al., 2013) and diabetes mellitus patients. In immunodeficient
peoples, onychomycosis caused by T. rubrum affect entire fingers
and toenails (Almeida, 2008; Baltazar et al., 2013), and it is
considered the most common and widespread fungal infectious
disease worldwide.
Infections caused by T. rubrum species are very difficult to
treat and very few numbers of antifungals available clinically
to control this infection (Bitencourt et al., 2013). The azole
group of antifungal agents such as ketoconazole and fluconazole
have been used for the treatment of various fungal infections
especially dermatomycosis (Aala et al., 2010). Azoles are synthetic
drugs and although effective, but, because of increased use,
azole resistant pathogens have been reported (Mishra and
Tiwari, 2011). Furthermore, they are generally known to cause
various side effects. Nowadays, the infectious to fungal diseases
become more dangerous, and a number of infections become
resistant to many classical clinically used antibiotics. Therefore,
the continuing efforts to find out new antifungal agents are
necessary and urgently needed. Natural products still remained
an important source of drug discovery, providing crucial and
unmatched chemical diversity. Most of the antimicrobial drugs
used today are derived from natural products or natural product
scaffolds (Mishra and Tiwari, 2011).
The violacein is a natural purple, blue pigment isolated from
various Gram-negative bacteria including Chromobacterium
violaceum, Collimonas sp., Duganella sp., Iodobacter fluviatile,
Janthinobacterium lividum, and Microbulbifer sp. (Wang et al.,
2012). Violacein exhibits many biological properties such
as broad-spectrum antimicrobial, antiviral, antiprotozoal, and
antioxidant activities (Wang et al., 2012), and exerts significant
cytotoxicity toward several tumor cell lines (Wang et al.,
2012). Moreover violacein recorded antifungal activity especially
against chytrid fungus Batrachochytrium dendrobatidis which is
responsible for the worldwide decline in amphibian populations
(Park et al., 2014). Various biological and pharmacological
properties of violacein have made it an attractive tool for medical
and biotechnological research (Wang et al., 2012).
For several years until now, combination therapy with
two or more antibiotics is used to prevent or delay the
emergence of drug-resistant strain to take advantage of antibiotic
synergism (Chambers, 2006). Recently, the combinations of
natural products and antibiotics were reported to enhance the
activity of classical antibiotics (Reuk-ngam et al., 2014). Thus,
the synergistic interactions of natural products and standard
antibiotics were a potential alternative approach to treating
various infectious diseases. In the view of our ongoing research
for promising antimicrobial agents and explore the novel
biological activity of violacein, we decided to study the synergistic
effects of violacein with four classical antifungal agents with
special reference to human pathogenic fungi T. rubrum.
Materials and Methods
Violacein
Violacein (Figure 1) used in the present study was isolated
from a novel strain of Chromobacterium violaceium isolated
from sediment sample collected from a clay mine acid lake
in Thiruvananthapuram district in Kerala, India (Lat_long =
8◦5553′′ N 76◦8577′′E). The culture was maintained in 0.1%
peptone watermedia (0.01 g peptone, 0.003 gNaCl/10ml distilled
water) in room temperature in small vials. It was sub-cultured
bimonthly. After 24 h fermentation in LB broth, the bacterial
biomass was separated through centrifugation the biomass was
extracted twice with ethanol. The ethanolic extract was filtered
through 0.22µm filter paper (Millipore) to avoid the cell detritus
and then dried in the rotavapour. The pure violacein was
precipitated by methanol water crystallization and then the
precipitate was washed with hexane and demineralized water.
Violacein obtained was then dried in an oven at 80◦C and kept in
a desiccator and its structure was confirmed by the spectroscopic
methods (1H NMR and MS).
Azole Agents
Ketoconazole, fluconazole, clotrimazole, and itraconazole
(Figure 1) were used as standard antifungal agents and were
purchased from Sigma Chemical Co. (St Louis, MO). Antifungal
agents were prepared as stock solutions at concentrations of
2mg/ml in dimethylsulfoxide for susceptibility testing and
checkerboard method, respectively.
Test Pathogens
The test dermatophyte T. rubrum (MTCC 296) was procured
fromMicrobial Type Culture Collection and Gene Bank (MTCC)
Division, CSIR-Institute of Microbial Technology (IMTECH),
Chandigarh, India. The strains were cultivated on Potato
dextrose agar (PDA) (Hi-media, Mumbai, India) and incubated
at 28◦C for 7–15 days. For all experiments, the strains were
cultivated on PDA and incubated at 28◦C as described above or
until the sporulation.
Preparation of Inoculum
T. rubrum colonies were covered with 5ml of sterile saline
solution (0.85%), the surface was gently scraped using a sterile
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FIGURE 1 | Chemical structure of violacein and azoles used in the present study. Violacein were isolated and purified from a novel strain of Chromobacterium
violaceum and azoles drugs were purchased from Sigma-Aldrich.
inoculating loop and the saline solution with fungal materials
was gently transferred to a sterile test tube. This suspension was
shaken for 2–3min using a vortex mixer, allowed to stand for
5min to allow hyphal fragments to fall out of the suspensions so
that the supernatant containing the conidia could be collected.
Inocula were standardized at 0.5 tube of McFarland scale (105
CFU/ml). Quantification was confirmed by inoculating 0.01ml
of a 1:100 dilution of each suspension onto PDA. The PDA plates
were incubated at 28◦C and the developments of fungal colonies
were examined daily.
Determination of Minimum Inhibitory
Concentration (MIC)
The MIC value of violacein and azole antibiotics were
performed using the microdilution assay as described in
M38-A2, Clinical and Laboratory Standards Institute (CLSI,
2008), with minor modifications. The medium used was RPMI
1640 with L-glutamine (Sigma-Aldrich, St. Louis, MO, USA)
buffered to pH 7.0 with 0.165M morpholine propanesulfonic
acid (MOPS) (Sigma-Aldrich, USA), supplemented with 2%
glucose. The T. rubrum cell suspension was prepared in a
0.85% saline solution. The suspension of conidia was then
transferred to sterile test tubes where they remained for
30min to separate the microconidia, which were lighter and
therefore, present in the supernatant. After that the separated
microconidia concentration was adjusted to obtain a final
concentration ranging from 3 × 103 to 6 × 103 CFU/ml.
Then these suspensions were diluted in RPMI 1640 (Sigma-
Aldrich, St. Louis, MO, USA) and inoculated on 96-well plates
that had been previously prepared with the test compounds
diluted at concentrations from 0.5 to 1000µg/ml. Positive
(medium with inoculum) and negative (medium alone) controls
were included in all experiments. The plates were incubated
for 7 days at 28◦C. The MIC reading was performed by
spectrophotometry at 600 nm. The MIC was defined as the
concentration of violacein/azoles that inhibit 90% of fungal
growth.
Minimum Fungicide Concentration (MFC)
Aliquot of 20µl from the wells that recorded no fungal growth
in MIC test was serially diluted and plated on a PDA plates and
incubated at 28◦C for 5 days. The MFC was defined as the lowest
violacein/azoles concentration that did not allow the growth of
any fungal colonies on the PDA plates after the incubation period
(Soares et al., 2014).
Synergistic Effect of Violacein and Azoles
The drug interaction activity was assessed using a checkerboard
method derived from a standardized procedure recommended
by the Clinical and Laboratory Standards Institute (M38-
A2) (CLSI, 2008). Briefly, the test was performed in the
same medium used for susceptibility testing. Volumes of
150µl of the MIC concentration of violacein and azoles were
dispensed in 96-well plates. To each well, 50µl of the fungal
suspension was added to produce a final concentration of
5 × 103 CFU/ml. The negative control contains 200µl of
RPMI while the positive control contains 150µl of RPMI
medium with 50µl of inoculum. The plates were incubated
at 28◦C, and the reading was completed after 5 days.
We conducted visual and spectrophotometric readings at
600 nm. To determine the effect of combinatorial fractions, we
calculated the fractional inhibitory concentration (FIC). The
FIC was calculated by taking the MIC of the compound in
combination/MIC of the compound alone. The sum of the
fractional inhibitory concentration (FIC) of each compound
consists of the fractional inhibitory concentration index: (The
MIC of compound A in combination/The MIC of compound
A alone) + (The MIC of compound B in combination/The
MIC of compound B alone). A synergistic relationship was
defined as FIC index ≤ 0.5, an additive relationship was
defined as 0.5 < FIC index ≤ 1.0, an indifferent relationship
was defined as 1.0 < FIC index ≤ 4.0, and an antagonistic
relationship was defined as FIC index >4.0 (Soares et al.,
2014).
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Time–kill Studies
The time–kill activity was determined to know the rate of killing
of T. rubrum conidia. A time–kill curve (CFU as a function
of time) is evaluated to study the rate and extent of reduction
in T. rubrum conidia when treated with violacein and azoles
individually and in combination. The time–kill was conducted
for 48 h in Potato Dextrose Broth (PDB). The concentrations
used are the MIC values of violacein and azole drugs alone and in
combination (see Table 1). An initial inoculum of approximately
1 × 106 CFU/ ml conidia was taken for all the experiments. At
predetermined time points (0, 2, 4, 6, 8, 12, 24, and 48 h), a
0.1ml sample was removed and serially diluted in normal saline
and plated onto PDA plates. Colony counts were determined
following 5 days of incubation at 30◦C. The broth without any
test compounds was used as the control. The data were plotted
as log CFU/ml vs. time (h) for each time point. Tests were
performed in triplicate (Khan and Ahmad, 2011).
Effects of the Combination on Mycelial Growth
Analysis of the influence of violacein and azole drugs on mycelial
growth was studied by assessing the mycelial dry weight of
T. rubrum in triplicate (Pereira et al., 2013). PDB (5ml) with
violacein and azoles individually and in combination and 0.5ml
of the inoculum suspension were added to sterile tubes. Control
tubes involved the use of sterile distilled water in place of the test
compounds. The tubes were incubated at 28◦C for 10 days, the
mycelia filtered through sterile filter paper (retention of particles:
10µm) and then dried at 50◦C for 15–20min. The filter paper
containing dry mycelia was weighed, and the percent of mycelia
produced was calculated, using the growth in the control tubes as
being 100% of potentially dry mycelial weight.
Effects of the Combination on Conidial
Germination
Violacein and azoles were tested to evaluate their impact on
the germination of T. rubrum conidia. Double concentrated
PDB (1ml) containing the violacein and azoles individually and
in combination was added to sterile tubes, mixed with 500µl
of fungal suspension and then immediately incubated at 28◦C.
Samples were taken at 24 h to record the number of germinated
and ungerminated conidia through the use of a hemocytometer
from which the percentage of germinated conidia was calculated.
The test was conducted in triplicate (Pereira et al., 2015).
Effect of Combination on the Release of
Intracellular Material
Measurements of the release of fungal intracellular material
absorbing at 260 nm from T. rubrum were conducted using
5ml aliquots of the fungal inocula after the addition of the
violacein and azoles alone and in combination. At different time
intervals (2, 4, and 6 h), fungal cells were centrifuged at 5000 rpm
for 5min, and the supernatant was examined by measuring
the absorbance at 260 nm with a UV-visible spectrophotometer
(Shimadzu). The flask without test violacein and azoles was
used as the control. Alcoholic potassium hydroxide solution
(25% diluted with ethanol at 70%) was used as the reference
compound since it causes 100% cellular leakage. Rate of release of
intracellular material absorbing at 260 nm, primarily nucleotides,
was calculated by comparing the test values with the lysing
agent which was considered to be 100%. The experiment was
performed in triplicate (Pereira et al., 2013).
Morphological Studies by Scanning Electron
Microscope (SEM)
The plates used for studying the antifungal activity by disc
diffusion were employed in the morphological studies using
SEM. Samples of mycelial growth were taken at the central,
intermediate, and peripheral zones of the colonies. SEM analysis
of adhesive tapes used to capture fungal structures was made
using a SEM (JEOL JSM 5600 LV Electron Microscopy (USA).
Tape fragments measuring 5–10mm in diameter bearing the
fungal structures were cut and mounted onto a 12mm metal
stub (Agar Scientific, Essex, England, pin stubs cod. G301F),
using double-sided carbon adhesive tape. The morphological
TABLE 1 | Synergistic effects of the violacein in combination with azole drugs against T. rubrum.
Test organism Agent MIC/MFC (µg/ml) FIC/FFC FICIb/FFCIc Outcome
Alone Combinationa
T. rubrum Violacein
Ketaconazole
32/64
1/2
2/4
0.25/0.25
0.06/0.06
0.13/0.13
0.19/0.19 Synergistic/synergistic
Violacein
Fluconazole
32/64
2/4
4/4
0.5/0.5
0.13/0.06
0.25/0.13
0.38/0.19 Synergistic/synergistic
Violacein
Clotrimazole
32/64
4/8
1/2
0.25/0.25
0.03/0.03
0.06/0.03
0.09/0.09 Synergistic/synergistic
Violacein
Itraconazole
32/64
2/2
8/8
0.25/0.5
0.25/0.13
0.13/0.25
0.38/0.38 Synergistic/synergistic
MIC/MFC value of violacein and azoles alone was conducted by micro broth dilution method and MIC/MFC value of the combination was conducted by checkerboard assay. FICI
index were obtained from the checkerboard assay: To evaluate the interaction of violacein with azoles against T. rubrum, checkerboard experiments were performed. FIC/FFC index =
(MIC/MFC of azoles in combination with violacein/MIC/MFC of azoles alone) + (MIC/MFC of violacein in combination with azoles/MIC/MFC of violacein alone). A FICI/FFCI ≤ 0.5 is
indicative of synergism.
aThe MIC and MFC of violacein in combination with azole.
bThe fractional inhibitory concentration index (FIC index).
cThe fractional fungicidal concentration index (FBC index).
Values in bold indicated best synergistic combination.
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characteristics of the hyphae, conidiophores, phialides, spores,
and conidia were determined with SEM analysis (Michaelsen
et al., 2010).
Cytotoxicity Test by MTT Assay
The MTT (3-(4, 5-dimethyl thiazol-2-yl)-2, 5-diphenyl
tetrazolium bromide) (Sigma-Aldrich) assay was employed
to determine the toxicity of violacein against FS (Foreskin)
normal fibroblast cell line, a normal human cells line (Anto et al.,
2003; Kumar et al., 2014).
Statistical Analyses
The statistical analyses were performed with SPSS (Version 17.0;
SPSS, Inc., Chicago, IL, USA). In the case of MIC, MFC, and FICI
experiments, when the results were different in both experiments,
we made another test for the final result. For time-kill assay, One-
Way ANOVA (Duncan’s multiple range) tests was used and the
data was presented as means ± standard deviations. Statistical
significance of the experiments was defined as p < 0.05.
Results
MIC and MFC
MIC and MFC value of violacein and four azole antibiotics used
alone for T. rubrum are shown in Table 1. The MIC/MFC value
of violacein against T. rubrum was 32/64µg/ml. The MIC/MFC
values of azole drugs ranges from 1 to 8µg/ml, and the highest
activity was recorded by ketoconazole 1µg/ml (Table 1).
Synergistic Effect by Checkerboard Assay
The synergistic activities of violacein and azole drugs from
the checkerboard assay against the T. rubrum are shown in
Table 1. FIC, FFC, FIC index, FFC index, and interpretations
for the activities of violacein and azole drugs against the T.
rubrum predominantly recorded the synergistic interaction. A
best synergistic interaction was recorded by the combination of
violacein and clotrimazole (Table 1).
Time-kill Assay
The time-kill assay of violacein and azoles alone and in
combination is shown in Figure 2. The combination of violacein
and azole drugs recorded significant reduction in the CFU/ml
when compared to the effect of individual compounds (violacein
and azoles) (Figure 2). For the combination of violacein and
ketoconazole, the significant reduction in the CFU/ml was
recorded between 6 and 12 h, whereas for violacein and
fluconazole it was between 12 and 24 h. The combination of
violacein and clotrimazole recorded best reduction in the colony
count between 4 and 12 h. But the significant reduction in the
colony count was recorded by violacein and itraconazole (4–6 h).
FIGURE 2 | Time–kill curves of violacein and azoles alone and in combination against T. rubrum. The experiments were performed in triplicates. Data are
expressed as mean ± standard deviation. CFU-Colony Forming Unit. Control, Violacein, Azole, MIC combination, Half MIC combination.
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Effects Combination of Violacein and Azoles on
Mycelial Growth
The impact of the combination of violacein and azole drugs on
the growth of mycelia was determined by measuring the mycelial
dry weight of T. rubrum after treatment (Figure 3). As shown
in Figure 3, the combination of violacein and azoles recorded
significant inhibition of the mycelial growth of T. rubrum (P <
0.05) as compared with that of individual compounds (100%
mycelia yield) and control. Best inhibition was recorded by the
combination of violacein and clotrimazole (Figure 3).
Effect of Combination on the Conidial
Germination
The percentage of germinated conidia of T. rubrum after the
treatment is recorded in Figure 4. The combination of violacein
and azole drugs significantly inhibited conidial germination (P <
0.05). Here also best inhibition was recorded by the combination
of violacein and clotrimazole (Figure 4).
Effect of Combination on the Release of
Intracellular Materials
The effect of violacein and azoles alone and in combination on
cell membrane and resulting impact on the release of intracellular
materials was initially determined by measurement of the release
of 260 nm absorbing intracellular material from T. rubrum
(Figure 5). From the results, it is clear that the combination of
violacein and azoles leads to an enhanced release of intracellular
materials from the cell compared to compounds alone and
control (no compounds) (P < 0.05). Release of intracellular
materials starts from 2 h onwards and reached maximum at 4 h
and then remain stable (Figure 5)
Morphological Changes Induced by the
Combination of Violacein and Azoles as Revealed
by SEM Analysis
SEM analysis of the morphological changes induced by violacein
and azoles revealed that the combination recorded significant
morphological changes in T. rubrum. Enhanced hyphal damages
and rupture were observed with the combination as compared
with that of individual compounds (Figure 6). Combinations
treated hyphae also recorded wrinkling of the cell surface and
emptying of the cytoplasmic content, which were not observed
on the smooth surfaces of untreated hyphae. Moreover, the
combination enhances severe damaged shown as collapse and
degradation of the cells. Drastic reduction of T. rubrum spores
number was also observed for the combination of violacein and
FIGURE 3 | Percentage of dry mycelial weight produced by T. rubrum
by the treatment of violacein and four azoles alone and in
combination. Control produced 100% of dry mycelial weight. Data are
expressed as mean ± standard deviation. Different letters in the superscript
were significantly different according to Duncan’s multiple range test
(p < 0.05).
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FIGURE 4 | Percentage of germinated conidia of T. rubrum by the treatment of violacein and four azoles alone and in combination. Data are expressed
as mean ± standard deviation. Different letters in the superscript were significantly different according to Duncan’s multiple range test (p < 0.05).
azoles (Figure 6), although to a lesser extent with ketoconazole
and fluconazole.
Cytotoxicity Assay of Violacein
The cytotoxic activity of violacein was confirmed using MTT
assay against the FS normal fibroblast cell line. The present results
clearly showed that violacein recorded no significant cytotoxicity
up to 100µg/ml (Figure 7). The data from MTT assay clearly
indicates that violacein may be safe against normal human cells.
Discussion
The novel development of strategies to manage various
pathogenic fungal infections may be an effective means for
ideal therapeutic interventions. Consequently, the aim of
novel antifungal strategies is to develop new drugs that
combine sustainability, high efficiency, relatively low toxicity,
safe for human beings, animals, plants, and environment with
comparatively low production cost. Human pathogenic fungal
infections are more prevalent in both developed and developing
nations (Cronin et al., 2014). According to World Health
Organization (WHO) more than 25% of the global populations
are infected with various dermatophytes (pathogenic fungi
affecting keratinized materials of our body) (Cronin et al.,
2014). Unlike human pathogenic bacteria, fungi are eukaryotic
organisms and the treatment to control these become more
limited due to the biochemical similarities between human and
fungal cells. In addition, treatment becomes more difficult due
to the position of infecting area especially beneath the nail
and this makes it difficult to administer therapeutic doses of
various topical therapies (Seebacher et al., 2008; Cronin et al.,
2014). Thus, superficial fungal infections of keratinized tissue
and mucous membranes caused by pathogenic dermatophytes
become one of the challenging fungal infections to treat.
The main therapies currently available to treat dermatophytic
fungi have concerns either due to their poor response to
the reappearance of infection reported in up to 40% of
cases. Moreover the treatment of this fungal infections require
high treatment costs, comprehensive treatment requirements
and severe side effects (e.g., hepatotoxicity) (Woodfolk, 2005;
Warshaw, 2006; Chang et al., 2007). The profound impact
dermatophytes have on a patient’s quality of life due to the
severe pain and physical deformation caused by the infection
surely warrants alternative drug that are safe and more effective
(Szepietowski and Reich, 2009). Due to the very high rate of
recurrence of superficial fungal infections and the increasing
antifungal resistance problems, in particular against the azoles,
new drugs alternatives with fungicidal activity are very much
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FIGURE 5 | Rate of release of intracellular material of T. rubrum
recorded absorbance at 260nm in the absence (control) and
presence of violacein/azoles alone and in combination. Data are
expressed as mean ± standard deviation. Different letters in the
superscript were significantly different according to Duncan’s multiple
range test (p < 0.05).
FIGURE 6 | Morphological analysis by SEM after the treatment of T. rubrum by violacein alone and in combination with azole drugs. (A) control, (B)
violacein alone, (C) violacein +ketoconazole, (D) violacein +fluconazole, (E) violacein +clotrimazole, and (F) violacein +itraconazole.
needed (Ghannoum et al., 2013; Tchernev et al., 2013). In
this background, the antifungal activity of violacein against T.
rubrum, one of the major human pathogenic dermatophytes
was evaluated on their own or in combination with four major
clinically used azole drugs.
An alternative approach to combat drug-resistant fungal
pathogens is the use of antifungal agents in combination with
natural compounds to reduce toxicity and the emergence of
multidrug resistance (Endo et al., 2010). In view of the lack of
novel drugs with different molecular targets and mechanism of
action, combination of two or more drug might be considered
as a viable strategy for therapy, considering the multiplicity
of fungal targets against which current agents are effective
(Mukherjee et al., 2005; Endo et al., 2010). The combinations
of the drug are described as synergy, indifferent, additive or
antagonistic. The main benefit of using drug combination is
the synergistic effect, in which the activity is greater than
the individual drugs (Endo et al., 2010). In current study
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FIGURE 7 | Cytotoxicity of violacein against normal human
cell line (Foreskin normal fibroblast) conducted by MTT
(3-(4, 5-dimethyl thiazol-2-yl)-2, 5- diphenyl tetrazolium
bromide) assay. All measurements were taken in replicates of
three, and results are expressed as arithmetic mean ± standard
error of the mean. (A) Bar diagram of the result at different
concentration and (B) representative confocal microscopic image of
cells.
violacein and azole combination recorded activity at very low
concentration than the individual compounds. The benefits of
using synergistic drug combination include a wider spectrum
of efficiency, improved safety and tolerability and an enhanced
reduction of antifungal resistance (Lewis and Kontoyiannis,
2001; Endo et al., 2010). In our study, we investigated the
synergistic effect of violacein and four clinically used azole drugs
(ketoconazole, fluconazole, itraconazole, and clotrimazole). We
mainly focused on the combinations of violacein with azoles
because azole is one of the most accepted antifungal agent
used for treating dermatophytes, especially in patients with the
immunocompromised condition.
In our study, significant synergy was recorded by violacein
in combination with azole antibiotics. This is in agreement
with the earlier studies that the efficacy of azole drugs can
be improved by certain natural products (Aala et al., 2010;
Endo et al., 2010). Violacein used in our study was a natural
product predominantly isolated from Chromobacterium spp.
and this compound significantly enhanced the activity the
four azole drugs employed in the current study. Positive
interactions in checkerboard microdilution were confirmed by
time-killing assay. Time-kill curves can provide growth kinetic
information over time. This method is often used to detect
the differences in the rate and extent of antifungal activity
over time (Jin et al., 2010). In the present study, there was an
excellent agreement between the FICI method and the time-kill
curves. The combination of violacein and azole drugs recorded
significant synergistic interaction against T. rubrum. Thus, the
combination of violacein with azole drugs represents an attractive
alternate approach for the development of new management
strategies for controlling superficial dermatophytic infections.
Previously the synergistic antibacterial activities of violacein with
antibiotics are reported (Subramaniam et al., 2014). Moreover,
the synergistic effect of violacein and azoles against medically
important dermatophytic fungi like T. rubrum is reported here
for the first time.
In case of dermatophytosis pathogenesis, dermatophytes
produce filamentous hyphae during the infection process in our
body. It is important because they can exacerbate the damage and
penetrate into the deeper layers keratinized tissues of our body
(Pereira et al., 2015). Therefore, the dry mycelial mass does not
reflect the total live cells, but equally important, it reflects the
production of the fungal cell material. In the present study, the
combination of violacein and azoles inhibited the fungal growth
by decreasing the dry mycelial production of T. rubrum. So the
present study clearly demonstrated that the combination will
help to control the growth of fungal hyphae and thus prevent the
occurrence of infections in deeper layers of our body.
T. rubrum conidia are considered as one of the primary
means of establishing dermatophytosis in humans and animals.
They adhere to epithelial cells of the keratinized tissues of
the host where they germinate and initiate an invasion of the
stratum corneum. Hyphae can grow in multiple directions and
form mycelium (Ohara and Tsuge, 2004). The findings of the
present study clearly demonstrated that the combination of
violacein and azoles inhibited the germination of conidia, and
this is of particular significance that this will prevent the further
dissemination of T. rubrum.
Ergosterol is a sterol found in the cell membranes of yeasts
and filamentous fungi and functions as an important regulator
of membrane fluidity. Changes in the ergosterol biosynthetic
pathway will also inhibit fungal growth (Van Minnebruggen
et al., 2010). The azoles mainly act through the inhibition
of lanosterol-14a-demethylase, a key enzyme involved in the
biosynthesis of ergosterol, an important component of the fungal
cell membrane (Martinez-Rossi et al., 2008). In T. rubrum,
azoles treatment significantly reduces the ergosterol level within
the cell, leading to the cell membrane perturbation. The azole
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FIGURE 8 | Proposed mechanism of action of the synergistic
combination of violacein and azoles. Where “V” denotes violacein and “A”
denotes azole drugs.
portion in the combination decreases the sterol concentration
which in turn leads to cell membrane perturbation (Uppuluri
et al., 2008). The resulted in the alteration of plasma membrane
permeability that allows violacein portion in the combination to
enter the cell and that may lead to the enhanced killing of T.
rubrum. The proposed mechanism of action of the synergistic
combination of violacein and azole is shown in Figure 8. Because
of these effects on fungal membranes, we investigated whether
violacein and azole alone and in combination damages the
cell membrane of T. rubrum by the detection of intracellular
components released into the external environment. These
cellular components represent primarily nucleotides, and that
recorded strong absorption at 260 nm. Our results clearly suggest
that violacein azole combination interferes with the integrity
of the cell membrane producing damage to the structure. We
also speculate that resulting alterations in the plasma membrane
permeability may allow increased concentrations of violacein to
enter the cell, resulting in enhanced fungal cell death. Moreover,
azoles reduce the sterol concentration in fungal cells and,
thereby, its combination with violacein renders the combination
fungicidal. In future research based on T. rubrum infected
animal models may resolve the in vivo efficacy of the synergistic
combination violacein and azoles.
The significant biological and pharmacological activities of
violacein have made it an attractive area for many medical
researchers. It is reported that intraperitoneal doses of violacein
up to 1mg/kg are not toxic in mouse blood, kidneys, or liver,
which provides evidence for the in vivo use of violacein as a
therapeutic agent with little side effects (Cazoto et al., 2011).
In the present also violacein was non-toxic to a normal healthy
human cell line (FS) up to 100µg/ml.
Conclusions
In our study, violacein exhibited significant antifungal activity,
and this proved its efficacy as potential antifungal agent.
Interestingly violacein exhibited strong synergistic interactions
with azole drugs against the T. rubrum. These results suggest
that the combination of violacein and azoles can be expected
to act synergistically in the treatment of dermatophytic
infections. Further investigation is required to examine the
effects of violacein and azoles combination against other
clinically relevant dermatophytes. The current studies also draw
attention for developing new compounds from natural source
especially violacein as antifungal agents in the management of
dermatophytosis. However, in vivo experimental evaluations are
needed to unfold the therapeutic potential of these agents in
combating such superficial fungal diseases.
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